The attorneys at Montgomery & Ponder, LLC are investigating cases related to Tasigna, a drug used to treat chronic myeloid leukemia. The drug is used during chemotherapy and is made by the pharmaceutical company Novartis, who reportedly made $1.7 billion from the product in 2016 alone.
Chronic myeloid leukemia is a type of cancer that starts in the blood-forming cells in the bone marrow, and Tasignawas approved by the FDA in 2007 to treat this form of cancer. The most severe side effect being seen from Tasignais atherosclerosis. Atherosclerosis is a severe hardening of the arteries, and in some cases this has occurred immediately upon taking the drug. This hardening comes from the arterial walls becoming narrow due to a buildup of plaque and white blood cells, which make the blood flow become impaired. This has led to patients suffering heart attacks, strokes, and even death.
Novartis agreed to pay $390 million to settle federal and state charges over claims that it illegally marketed drugs, including Tasigna, in 2015. Between 2007 and 2012, Novartis was accused of paying pharmacies to recommend their drugs to patients using Medicaid and Medicare.
Complications from Tasigna include:
- Night sweats
- Pale skin
- Muscle and joint pain
More serious complications include:
- Pancreas inflammation
- Bleeding in the brain
- Decreased blood flow in the leg, heart, or brain
- Low blood count which can cause bleeding, blood in urine, and weakness
- QT prolongation that can cause sudden death
Hundreds of cases of atherosclerosis have been reported resulting from the use of the drug Tasigna. If you or a loved one sustained an injury related to Tasigna during the course of chemotherapy treatment, please contact the attorneys at Montgomery & Ponder, LLC at (205) 377-5004.